PGR and ductal breast carcinoma in situ: In this large, randomised, double-blind, placebo-controlled trial comparing anastrozole with tamoxifen in women with ER-positive or PgR-positive DCIS treated by wide local excision with or without breast radiotherapy, the non-inferiority of anastrozole to tamoxifen was demonstrated, but a significant superiority efficacy was not, although we noted a slightly lower recurrence rate for anastrozole.